Exscientia Presents Three Posters Demonstrating Potential of Precision Medicine Platform in Drug Discovery at the American Association of Cancer Research Annual Meeting 2022Business Wire • 04/08/22
Exscientia plc (EXAI) CEO Andrew Hopkins on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/24/22
Exscientia to Report Fourth Quarter and Year End 2021 Financial Results on March 23, 2022Business Wire • 03/16/22
Exscientia and University of Oxford Launch “Xcellomics” Program to Expedite Early-Stage Academic Research and Translate Novel Biology Into Future Drug DiscoveryBusiness Wire • 03/10/22
Exscientia to Highlight Precision Medicine Platform and Pipeline Data at the American Association of Cancer Research Annual Meeting 2022Business Wire • 03/08/22
Is Exscientia PLC Sponsored ADR (EXAI) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 02/09/22
Professor Charlotte Deane Joins Exscientia as Chief Scientist of Biologics AIBusiness Wire • 01/19/22
Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicinesGlobeNewsWire • 01/07/22
Exscientia to Present at Evercore ISI 4th Annual HealthCONx Virtual ConferenceBusiness Wire • 11/23/21
Exscientia plc (EXAI) CEO Andrew Hopkins on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/18/21
Exscientia to Report Third Quarter 2021 Financial Results on November 17, 2021Business Wire • 11/10/21
Publication of EXALT-1 Trial in Cancer Discovery Demonstrates First AI-Supported Functional Precision Medicine Platform to Improve Cancer Treatment OutcomesBusiness Wire • 10/11/21
Exscientia Announces Closing of $510.4 Million Aggregate Financing, Consisting of $350.4 Million Upsized Initial Public Offering With Full Exercise of Underwriters' Option to Purchase Additional ADSs and $160.0 Million Concurrent Private PlacementBusiness Wire • 10/05/21